Behavioral Weight Loss and Stigma Reduction
Obesity
Bottom Line
View on ClinicalTrials.gov: NCT03704064 ↗Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Stigma-Reduction Intervention (Behavioral); Behavioral Weight Loss (BWL) (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Pennsylvania
- Primary completion
- Jul 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Weight Change at Week 72 |
-7.16; -5.19 | 0.14 |
| SECONDARY Loss of 5% or Greater of Initial Body Weight at Week 72 |
20; 21 | 0.89 |
| SECONDARY Loss of 10% or Greater of Initial Body Weight at Week 72 |
14; 7 | 0.06 |
| SECONDARY Percent Weight Change at Week 46 |
-8.2; -5.9 | 0.07 |
| SECONDARY Percent Weight Change at Week 20 |
-6.7; -5.7 | 0.42 |
| SECONDARY Loss of 5% or Greater of Initial Body Weight at Week 46 |
28; 22 | 0.24 |
| SECONDARY Loss of 10% or Greater of Initial Body Weight at Week 46 |
15; 9 | 0.24 |
| SECONDARY Loss of 5% or Greater of Initial Body Weight at Week 20 |
31; 22 | 0.07 |
| SECONDARY Loss of 10% or Greater of Initial Body Weight at Week 20 |
11; 5 | 0.21 |
| SECONDARY Change in Minutes of Physical Activity (Accelerometer) at Week 72 |
9.6; 7.2; 9.4; 8.4; 3.2; -10.2 | 0.62 |
| SECONDARY Change in Minutes of Physical Activity (Accelerometer) at Week 46 |
9.5; 5.4; 9.9; 10.5; 0.6; -17.9 | 0.46 |
| SECONDARY Change in Minutes of Physical Activity (Accelerometer) at Week 20 |
11.4; 8.8; 10.5; 9.9; 10.6; 4.7 | 0.63 |
| SECONDARY Change in Energy Expenditure at Week 72 |
314.8; 307.5 | 0.84 |
| SECONDARY Change in Energy Expenditure at Week 46 |
148.7; 260.4 | 0.53 |
| SECONDARY Change in Energy Expenditure at Week 20 |
452.5; 289.3 | 0.27 |
| SECONDARY Change in Exercise Self-efficacy at Week 72 |
-9.4; -15.0 | 0.22 |
| SECONDARY Change in Exercise Self-efficacy at Week 46 |
-10.6; -15.9 | 0.24 |
| SECONDARY Change in Exercise Self-efficacy at Week 20 |
1.1; -2.0 | 0.48 |
| SECONDARY Change in Eating Self-efficacy at Week 72 |
6.5; 1.7 | 0.16 |
| SECONDARY Change in Eating Self-efficacy at Week 46 |
5.8; -1.0 | 0.045 sig |
| SECONDARY Change in Eating Self-efficacy at Week 20 |
12.3; 8.6 | 0.27 |
| SECONDARY Change in Triglycerides at Week 72 |
-9.9; -13.7 | 0.72 |
| SECONDARY Change in Triglycerides at Week 20 |
-10.9; -7.7 | 0.67 |
| SECONDARY Change in Blood Pressure at Week 72 |
-5.0; -5.6; -1.9; -2.0 | 0.80 |
| SECONDARY Change in Blood Pressure Week 20 |
-9.7; -5.4; -3.5; -3.6 | 0.07 |
| SECONDARY Change in Weight Bias Internalization Scale Score at Week 72 |
-1.7; -1.5 | 0.30 |
| SECONDARY Change in Weight Bias Internalization Scale Score at Week 46 |
-1.5; -1.4 | 0.67 |
| SECONDARY Change in Weight Bias Internalization Scale Score at Week 20 |
-1.4; -1.2 | 0.45 |
| SECONDARY "Remission" of Elevated Weight Bias Internalization at Week 72 |
28; 26 | 0.38 |
| SECONDARY "Remission" of Elevated Weight Bias Internalization at Week 46 |
24; 25 | 0.95 |
| SECONDARY "Remission" of Elevated Weight Bias Internalization at Week 20 |
25; 26 | 0.99 |
| SECONDARY Change in Weight Self-stigma Scores at Week 72 |
-9.7; -6.7; -5.0; -3.8; -4.7; -2.9 | 0.06 |
| SECONDARY Change in Weight Self-stigma Scores at Week 46 |
-8.5; -5.5; -4.0; -2.8; -4.5; -2.7 | 0.05 |
| SECONDARY Change in Weight Self-stigma Scores at Week 20 |
-8.2; -5.5; -4.6; -3.2; -3.6; -2.3 | 0.07 |
| SECONDARY Treatment Acceptability at Week 20 |
6.4; 5.8; 6.1; 5.9; 6.1; 4.6 | 0.04 sig |
| SECONDARY Treatment Acceptability at Week 72 |
6.1; 5.8; 6.0; 5.7; 5.9; 4.1 | 0.24 |
Summary
Eligibility Criteria
Inclusion Criteria
- Eligible participants will be men and women ages 18 years and older.
- Participants must have obesity, defined as a BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 with an obesity-related comorbidity.
o Obesity-related comorbidities (which confer added CVD risk) will include:
- coronary heart disease;
- other atherosclerotic disease;
- sleep apnea;
- hypercholesteremia (i.e., high cholesterol, as diagnosed by doctor and/or if taking medication to lower cholesterol);
- and components of the metabolic syndrome, including hypertension (SBP ≥130, DBP ≥80 mm Hg, diagnosed by doctor and/or if taking anti-hypertensive medication); fasting blood glucose of 100-125 mg/dL (or prediabetes, diagnosed by doctor),; low HDL cholesterol ( 150 mg/dL, i.e., dyslipidemia diagnosed by doctor or taking medication to treat dyslipidemia), or elevated waist circumference (≥40 in for men, ≥35 in for women),.
- Eligible participants must also report a history of experiencing weight bias as assessed by self-report questionnaire and in-person interview, and have elevated levels of WBI as indicated by an average score of 4 (midpoint) or above on the Weight Bias Internalization Scale (WBIS) and by in-person interview.
- Participants must be seeking weight loss.
- If currently taking medications, dosages must be stable for at least 3 months.
- Participants will be eligible to participate if they exhibit mild to moderate severity of depression, anxiety, or binge eating disorder, as determined by the behavioral evaluation and the screening measures (Beck Depression Inventory-II and Questionnaire for Eating and Weight Patterns; see below for details). Elevated WBIS scores are often associated with these variables.
- Participants taking anti-depressant medication will be eligible if their dose has been stable for a minimum of 3 months.
Eligible female patients will be:
- non-pregnant and non-lactating
- surgically sterile or postmenopausal, or they will agree to continue to use a method of birth control during the study
Participants must:
- have a PCP who is responsible for providing routine care
- have reliable telephone service and/or email access with which to be in contact with the study team
- understand and be willing to comply with all study-related procedures and agree to participate in the study by giving written informed consent
Exclusion Criteria
Applicants will be excluded if they have:
- a diagnosis of type I or II diabetes (for type II diabetes, blood glucose ≥126 mg/dL or A1C ≥6.5);
- uncontrolled hypertension (blood pressure ≥ 160/100 mm Hg);
- experienced a cardiovascular event (e.g., stroke, myocardial infarction) in the last 12 months;
- lost and maintained ≥ 5% of their initial weight in the last 3 months or ≥ 10% in the past 2 years;
- or have participated in individual or group psychotherapy related to weight in the last 3 months (due to the potentially confounding effects of receiving a simultaneous cognitive-behavioral intervention).
o Participants who have recently received or are currently receiving therapy for a pre-existing mental health issue unrelated to weight (e.g., psychotherapy for depression or anxiety, or marriage, grief, or career counseling) may be eligible if the therapy is deemed by the Principal Investigator to be unlikely to affect weight, eating habits, or physical activity.
- Applicants with severe symptoms of mood (BDI-II score ≥ 29), anxiety, or binge eating disorder, and any severity of thought or substance use disorders will not be accepted into the study, as these symptoms may interfere with individuals' ability to adhere to a weight loss program.
o Clinician judgment will be used to determine severity of mood disorder symptoms independent from obesity-related concerns and complications (e.g., fatigue), and decisions about applicants' eligibility based on psychiatric symptoms will fall within the Principal Investigator's discretion.
- Individuals with bulimia nervosa will not be eligible to partici
Data sourced from ClinicalTrials.gov (NCT03704064). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.